证券代码：300294 证券简称：博雅生物 公告编号：2025-069 华润博雅生物制药集团股份有限公司 关于持股5%以上股东部分股份质押及解除司法冻结的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）近日收到 5%以上股 东深圳市高特佳投资集团有限公司（以下简称高特佳集团）出具的《关于部分股 份质押及解除司法冻结的告知函》，获悉高特佳集团将所持有公司的部分股份进 行质押及部分股份解除司法冻结，具体事项如下： 一、股东股份质押基本情况 （一）股东本次股份质押基本情况 2025 年 10 月 21 日，高特佳集团将其持有公司的无限售条件流通股 1,855,369 股（占公司总股本的 0.37%）质押给苏州诚河清洁设备有限公司进行融资，具体 情况如下： | | 是否为 | | | | | 是 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股 | 控股股 | | | | 是否为 | 否 | | 质 | | ...

Core Viewpoint - The company is making steady progress on its C1 esterase inhibitor research project and aims to enhance its product structure and core competitiveness through increased R&D efforts [1] Summary by Categories R&D Progress - The C1 esterase inhibitor is progressing smoothly according to the company's statement on the investor interaction platform [1] - The company plans to accelerate the new product launch process as part of its strategy to broaden its product structure [1] Future Expectations - The company acknowledges that the development and approval of new products is a lengthy and high-risk process, indicating that there are uncertainties involved [1] - The company will provide timely updates based on the progress of product development [1]

证券日报网讯博雅生物（300294）10月20日在互动平台回答投资者提问时表示，公司会紧紧围绕依据战 略目标，结合政策环境、市场环境等制定适合公司发展的经营策略，做好经营管理，切实保障股东及公 司的权益。 ...

10月15日，博雅生物涨0.08%，成交额6316.34万元。两融数据显示，当日博雅生物获融资买入额 1085.76万元，融资偿还871.71万元，融资净买入214.05万元。截至10月15日，博雅生物融资融券余额合 计6.71亿元。 融资方面，博雅生物当日融资买入1085.76万元。当前融资余额6.69亿元，占流通市值的5.35%，融资余 额超过近一年80%分位水平，处于高位。 分红方面，博雅生物A股上市后累计派现10.07亿元。近三年，累计派现4.89亿元。 融券方面，博雅生物10月15日融券偿还1700.00股，融券卖出900.00股，按当日收盘价计算，卖出金额 2.23万元；融券余量9.44万股，融券余额233.92万元，超过近一年70%分位水平，处于较高位。 资料显示，华润博雅生物制药集团股份有限公司位于江西省抚州市抚州高新技术产业开发区惠泉路333 号，成立日期1993年11月6日，上市日期2012年3月8日，公司主营业务涉及血液制品业务、糖尿病用药 业务、生化类用药业务、化学药业务以及复大医药经销业务。主营业务收入构成为：血液制品业务 84.58%，生化类用药业务8.63%，经销业务6.12%， ...

Core Insights - The appointment of Cheng Jie as the new president of China Resources Pharmaceutical signifies a strategic shift as the company faces challenges in traditional business growth and profitability amidst industry transformation [1][2][11] - The company reported a "revenue growth without profit increase" in its recent half-year report, with total revenue reaching 131.87 billion yuan, a 2.5% year-on-year increase, while net profit dropped by 20.3% to 2.08 billion yuan [2][7] - Cheng Jie, who has a strong background within the company, is expected to leverage his experience to navigate the current challenges and drive innovation and growth [4][19] Company Performance - China Resources Pharmaceutical's revenue has shown steady growth, increasing from 232.20 billion yuan in 2022 to 257.67 billion yuan in 2024, with an average annual growth rate of over 5% [7] - However, net profit has fluctuated, with a 13.06% decline in 2024 to 3.35 billion yuan and a further drop of 20.25% in the first half of 2025 [7][8] - The decline in profit is attributed to one-time impairment losses and rigid expense growth, with a net loss of 1.09 billion yuan in other income and losses reported for the first half of 2025 [7][8] Strategic Initiatives - The company has been actively pursuing mergers and acquisitions, with significant transactions including the acquisition of 100% of Green Cross Hong Kong for 1.82 billion yuan and a 28% stake in Tian Shi Li Pharmaceutical for 6.21 billion yuan [9][10] - Despite the expansion through acquisitions, the company is now shifting focus towards optimizing its asset structure by divesting non-core and loss-making businesses to enhance operational efficiency and profitability [10][15] - Cheng Jie is tasked with balancing the expansion from acquisitions with the need for profit growth, as well as addressing potential impairment risks associated with goodwill from these acquisitions [11][19] Industry Context - The Chinese pharmaceutical distribution market is experiencing maturation and differentiation, presenting structural opportunities for leading companies like China Resources Pharmaceutical [12] - Collaborations with multinational pharmaceutical companies are increasing, as these companies seek to focus on core products and leverage local distribution expertise [12][13] - The industry is transitioning from a phase of scale expansion to one of high-quality development, emphasizing the need for new products, channels, and innovative service models [14][15] Innovation and R&D - China Resources Pharmaceutical is enhancing its pharmaceutical business through initiatives such as establishing a 1 billion yuan investment fund focused on innovative drugs and high-end medical devices [17] - The company is also pursuing partnerships for innovative drug development, such as a collaboration with Nanjing Ai Er Pu for a heart failure treatment [17][19] - However, the company faces challenges in its R&D efforts, with a significant portion of its pipeline still focused on generic drugs rather than innovative products, which may hinder its competitive edge in a rapidly evolving market [18][19]

证券日报网讯博雅生物（300294）10月14日在互动平台回答投资者提问时表示，公司密切关注市场环境 及政策变化，目前公司各项生产经营正常有序。 ...

证券日报网讯博雅生物10月13日在互动平台回答投资者提问时表示，公司2025年9月30日含信用账户合 并名册的股东人数为30204户。 （文章来源：证券日报） ...

中信证券股份有限公司 根据《深圳证券交易所创业板股票上市规则》（以下简称"《股票上市规则》"） 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下简称"《上市公司规范运作》"）等相关规定，中信证券股份有限公司（以 下简称"中信证券"或"保荐机构"）作为华润博雅生物制药集团股份有限公司（以 下简称"华润博雅生物"或"公司"）的持续督导保荐机构，对公司使用银行承兑汇 票支付募集资金投资项目资金并以募集资金等额置换进行了核查。具体情况如下： 一、2018 年非公开发行募集资金基本情况 根据公司 2017 年第二次临时股东大会会议决议及中国证券监督管理委员会 《关于核准博雅生物制药集团股份有限公司非公开发行股票的批复》（证监许可 〔2018〕117 号），核准公司非公开发行不超过 3,750 万股股票。2018 年 4 月 4 日博雅生物制药集团股份有限公司完成了本次非公开发行，实际发行 32,247,662 股，每股发行价格 31.01 元。公司于 2018 年 4 月 4 日收到长城证券股份有限公 司汇缴的出资方认购款人民币 999,999,998.62 元扣除承销和保荐费用人民币 ...

Group 1 - The company emphasizes the importance of market value management, focusing on enhancing its core business and improving operational quality as key measures for value management [2] - The company aims to strengthen its core competitiveness, divest non-core assets, and maintain stable cash dividends to actively enhance its value and promote sustainable development [2]

Core Viewpoint - The company maintains an open and proactive attitude towards opportunities that align with its long-term development plans, focusing on strengthening its core blood products business and enhancing operational performance through both organic and external growth strategies [2] Company Summary - As of now, the company operates a total of 21 plasma collection stations, including 4 under the Green Cross brand [2] - In the first half of 2025, the raw plasma collection volume reached 320.39 tons, representing a year-on-year increase of 7.2%, which is higher than the industry average growth rate [2] Industry Summary - The company is committed to continuous efforts in both internal and external development to elevate its operational performance to new heights [2]